Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Kowloon, Hong Kong.
J Antimicrob Chemother. 2012 Sep;67(9):2101-6. doi: 10.1093/jac/dks171. Epub 2012 May 29.
Problems of vancomycin non-susceptible Staphylococcus aureus (VISA) and subsequent treatment failure are increasing. This study aimed to observe development and loss of vancomycin non-susceptibility, determine exposure time needed for resistance development, and follow mutations in the VraSR and GraSR two-component systems during these processes.
Sequences of vraS, graR and rpoB, proposed as critical sites of mutation associated with non-susceptibility development, were compared in susceptible clinical methicillin-resistant S. aureus isolates both initially and following vancomycin induction and its withdrawal, to identify mutations. Mutations were correlated with exposure time, increase in vancomycin MIC and phenotypic changes.
Both time required for heterogeneous VISA and VISA development, and maximum MIC attained (6-20 mg/L) varied between strains. Sequence analysis revealed the presence of stop codons in an initial strain with delayed non-susceptibility development. Other changes in vraS and graR occurred during VISA development in all isolates. After removal of vancomycin pressure, most strains reverted to susceptibility accompanied by emergence of stop codons in both vraS and graR. One strain not displaying stop codons remained resistant in the absence of vancomycin pressure. A substitution in GraR (D148Q) appeared to be associated with an elevated MIC (20 mg/L). No rpoB mutations were observed throughout VISA development.
Vancomycin non-susceptibility developed in all strains tested. Mutations in vraS and graR appeared to be essential for VISA development, with stop codons playing an important role in delaying non-susceptibility development and reversion. Absence of mutations in rpoB suggests that these are not essential for vancomycin resistance. Further work is required to confirm consistent changes involved in non-susceptibility development.
万古霉素不敏感金黄色葡萄球菌(VISA)及其后续治疗失败的问题日益增多。本研究旨在观察万古霉素不敏感性的发展和丧失,确定产生耐药性所需的暴露时间,并在这些过程中跟踪 VraSR 和 GraSR 双组分系统中的突变。
比较了初始时和万古霉素诱导及其撤除后,对临床分离的敏感耐甲氧西林金黄色葡萄球菌(MRSA)中,与不敏感性发展相关的突变的关键位点 vraS、graR 和 rpoB 的序列,以确定突变。将突变与暴露时间、万古霉素 MIC 增加和表型变化相关联。
异质 VISA 和 VISA 发展所需的时间以及达到的最大 MIC(6-20mg/L)在不同菌株之间有所不同。序列分析显示,在延迟不敏感发展的初始菌株中存在终止密码子。在所有分离株中,VISA 发展过程中 vraS 和 graR 也发生了其他变化。在去除万古霉素压力后,大多数菌株恢复了敏感性,同时在 vraS 和 graR 中都出现了终止密码子。在没有万古霉素压力的情况下,一个不显示终止密码子的菌株仍然具有耐药性。GraR 中的一个取代(D148Q)似乎与 MIC 升高(20mg/L)有关。在 VISA 发展过程中没有观察到 rpoB 突变。
所有测试的菌株都出现了万古霉素不敏感性。vraS 和 graR 的突变似乎是 VISA 发展所必需的,终止密码子在延迟不敏感性发展和恢复方面起着重要作用。rpoB 中没有突变表明其对万古霉素耐药性不是必需的。需要进一步研究以确认不敏感性发展中涉及的一致变化。